Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

Jerry S Powell, Neil C. Josephson, Doris Quon, Margaret V. Ragni, Gregory Cheng, Ella Li, Haiyan Jiang, Lian Li, Jennifer A. Dumont, Jaya Goyal, Xin Zhang, Jurg Sommer, Justin McCue, Margaret Barbetti, Alvin Luk, Glenn F. Pierce

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated subjects with severe hemophilia A investigated safety and pharmacokinetics of rFVIIIFc. Sixteen subjects received a single dose of rFVIII at 25 or 65 IU/kg followed by an equal dose of rFVIIIFc. Most adverse events were unrelated to study drug. None of the study subjects developed anti-rFVIIIFc antibodies or inhibitors. Across dose levels, compared with rFVIII, rFVIIIFc showed 1.54- to 1.70-fold longer elimination t 1/2, 1.49- to 1.56-fold lower clearance, and 1.48- to 1.56-fold higher total systemic exposure. rFVIII and rFVIIIFc had comparable dose-dependent peak plasma concentrations and recoveries. Time to 1% FVIII activity above baseline was ∼ 1.53- to 1.68-fold longer than rFVIII across dose levels. Each subject showed prolonged exposure to rFVIIIFc relative to rFVIII. Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377.

Original languageEnglish (US)
Pages (from-to)3031-3037
Number of pages7
JournalBlood
Volume119
Issue number13
DOIs
StatePublished - Mar 29 2012

Fingerprint

Factor VIII
Hemophilia A
Safety
Recombinant Fusion Proteins
Pharmacokinetics
Hemostatics
Intravenous Injections
Half-Life
Anti-Idiotypic Antibodies
Immunoglobulin G
Plasmas
Recovery
Molecules
Antibodies
Therapeutics
Pharmaceutical Preparations
factor VIII-Fc fusion protein

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Powell, J. S., Josephson, N. C., Quon, D., Ragni, M. V., Cheng, G., Li, E., ... Pierce, G. F. (2012). Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood, 119(13), 3031-3037. https://doi.org/10.1182/blood-2011-09-382846

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. / Powell, Jerry S; Josephson, Neil C.; Quon, Doris; Ragni, Margaret V.; Cheng, Gregory; Li, Ella; Jiang, Haiyan; Li, Lian; Dumont, Jennifer A.; Goyal, Jaya; Zhang, Xin; Sommer, Jurg; McCue, Justin; Barbetti, Margaret; Luk, Alvin; Pierce, Glenn F.

In: Blood, Vol. 119, No. 13, 29.03.2012, p. 3031-3037.

Research output: Contribution to journalArticle

Powell, JS, Josephson, NC, Quon, D, Ragni, MV, Cheng, G, Li, E, Jiang, H, Li, L, Dumont, JA, Goyal, J, Zhang, X, Sommer, J, McCue, J, Barbetti, M, Luk, A & Pierce, GF 2012, 'Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients', Blood, vol. 119, no. 13, pp. 3031-3037. https://doi.org/10.1182/blood-2011-09-382846
Powell, Jerry S ; Josephson, Neil C. ; Quon, Doris ; Ragni, Margaret V. ; Cheng, Gregory ; Li, Ella ; Jiang, Haiyan ; Li, Lian ; Dumont, Jennifer A. ; Goyal, Jaya ; Zhang, Xin ; Sommer, Jurg ; McCue, Justin ; Barbetti, Margaret ; Luk, Alvin ; Pierce, Glenn F. / Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. In: Blood. 2012 ; Vol. 119, No. 13. pp. 3031-3037.
@article{bf11142e51e2461887669f2c7a59ba94,
title = "Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients",
abstract = "Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated subjects with severe hemophilia A investigated safety and pharmacokinetics of rFVIIIFc. Sixteen subjects received a single dose of rFVIII at 25 or 65 IU/kg followed by an equal dose of rFVIIIFc. Most adverse events were unrelated to study drug. None of the study subjects developed anti-rFVIIIFc antibodies or inhibitors. Across dose levels, compared with rFVIII, rFVIIIFc showed 1.54- to 1.70-fold longer elimination t 1/2, 1.49- to 1.56-fold lower clearance, and 1.48- to 1.56-fold higher total systemic exposure. rFVIII and rFVIIIFc had comparable dose-dependent peak plasma concentrations and recoveries. Time to 1{\%} FVIII activity above baseline was ∼ 1.53- to 1.68-fold longer than rFVIII across dose levels. Each subject showed prolonged exposure to rFVIIIFc relative to rFVIII. Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377.",
author = "Powell, {Jerry S} and Josephson, {Neil C.} and Doris Quon and Ragni, {Margaret V.} and Gregory Cheng and Ella Li and Haiyan Jiang and Lian Li and Dumont, {Jennifer A.} and Jaya Goyal and Xin Zhang and Jurg Sommer and Justin McCue and Margaret Barbetti and Alvin Luk and Pierce, {Glenn F.}",
year = "2012",
month = "3",
day = "29",
doi = "10.1182/blood-2011-09-382846",
language = "English (US)",
volume = "119",
pages = "3031--3037",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

AU - Powell, Jerry S

AU - Josephson, Neil C.

AU - Quon, Doris

AU - Ragni, Margaret V.

AU - Cheng, Gregory

AU - Li, Ella

AU - Jiang, Haiyan

AU - Li, Lian

AU - Dumont, Jennifer A.

AU - Goyal, Jaya

AU - Zhang, Xin

AU - Sommer, Jurg

AU - McCue, Justin

AU - Barbetti, Margaret

AU - Luk, Alvin

AU - Pierce, Glenn F.

PY - 2012/3/29

Y1 - 2012/3/29

N2 - Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated subjects with severe hemophilia A investigated safety and pharmacokinetics of rFVIIIFc. Sixteen subjects received a single dose of rFVIII at 25 or 65 IU/kg followed by an equal dose of rFVIIIFc. Most adverse events were unrelated to study drug. None of the study subjects developed anti-rFVIIIFc antibodies or inhibitors. Across dose levels, compared with rFVIII, rFVIIIFc showed 1.54- to 1.70-fold longer elimination t 1/2, 1.49- to 1.56-fold lower clearance, and 1.48- to 1.56-fold higher total systemic exposure. rFVIII and rFVIIIFc had comparable dose-dependent peak plasma concentrations and recoveries. Time to 1% FVIII activity above baseline was ∼ 1.53- to 1.68-fold longer than rFVIII across dose levels. Each subject showed prolonged exposure to rFVIIIFc relative to rFVIII. Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377.

AB - Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated subjects with severe hemophilia A investigated safety and pharmacokinetics of rFVIIIFc. Sixteen subjects received a single dose of rFVIII at 25 or 65 IU/kg followed by an equal dose of rFVIIIFc. Most adverse events were unrelated to study drug. None of the study subjects developed anti-rFVIIIFc antibodies or inhibitors. Across dose levels, compared with rFVIII, rFVIIIFc showed 1.54- to 1.70-fold longer elimination t 1/2, 1.49- to 1.56-fold lower clearance, and 1.48- to 1.56-fold higher total systemic exposure. rFVIII and rFVIIIFc had comparable dose-dependent peak plasma concentrations and recoveries. Time to 1% FVIII activity above baseline was ∼ 1.53- to 1.68-fold longer than rFVIII across dose levels. Each subject showed prolonged exposure to rFVIIIFc relative to rFVIII. Thus, rFVIIIFc may offer a viable therapeutic approach to achieve prolonged hemostatic protection and less frequent dosing in patients with hemophilia A. This trial was registered at www.clinicaltrials.gov as NCT01027377.

UR - http://www.scopus.com/inward/record.url?scp=84859197329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859197329&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-09-382846

DO - 10.1182/blood-2011-09-382846

M3 - Article

VL - 119

SP - 3031

EP - 3037

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -